The withdrawal follows feedback from the EMA’s Committee for Medicinal Products for Human Use (CHMP), which indicated it would not be able to give a positive opinion on the application at this time.
The company continues to develop blarcamesine clinically and aims to advance potential treatment options for patients with early Alzheimer’s disease, supported by feedback from patients and organizations such as Alzheimer Europe.
Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, said, “We remain dedicated to advancing the development of innovative oral therapies for patients living with early Alzheimer’s disease and to continuing our engagement with regulatory authorities.”
In intraday trading, Anavex Life Sciences Corp. (NASDAQ: AVXL) shares fell 27.68 percent to $3.03, down $1.16 from the previous close of $4.19.
 has withdrawn its application for EU marketing approval of blarcamesine as an add-on treatment for early Alzheimer’s disease after the EMA’s committee indicated it could not support the application.){kind=link}